Esoteric testing market Statistical and Competitive Analysis Report with Top Companies

Increasing incidences of rare and complex diseases coupled with growing awareness about early disease diagnosis and treatment will drive esoteric testing market over the forecast period. According to European Commission, nearly 27 to 36 million people suffer from rare disease in European region. Rapidly improving healthcare sector in developing countries along with rising number of sophisticated laboratories offering advanced services will favour industry growth. Growing number of baby boomers prone to suffer from several chronic conditions will act as high impacting factor for industry growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1922

Infectious disease and immunology segment accounted for around 28% market share in 2017 owing to high prevalence of infectious diseases coupled with high demand for advanced molecular tests. Availability of immunology laboratory services for every medical specialty will positively impact segment growth in the foreseeable future.
ELISA business segment held over 20% of business share in 2017 and will witness more than 9.5% growth from 2018 to 2024. Moreover, ELISA is common technique for basic research, high throughput screening performed in laboratories, and drug discovery program. New developments in biomarker field leading to availability of new targets will generate revenue growth for the segment.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

Myriad Genetics, Litholink / Laboratory Corporation of America, Mayo Medical Laboratories, Miraca Holdings Inc., Nordic, Immunological laboratories BV, Quest Diagnostics, Genomic Health, ARUP Laboratories, ACM Global Laboratories, American, Esoteric Laboratories, Fulgent Genetics, OPKO Health, Inc.

Chemiluminescence business segment dominated esoteric testing industry in 2017 and is anticipated to witness over 10% CAGR growth owing to high adoption of chemiluminescence in esoteric testing due to its high efficiency along with necessity of small sample. Superior sensitivity and accuracy delivered by this technology using low analyte concentration will further stimulate business growth.
Globally, growing awareness regarding early disease diagnosis and treatment coupled with rising incidences of cancer will drive oncology segment growth over the forecast timeframe. Introduction of esoteric tests such as BRCAvantage developed by Quest Diagnostics for patients suffering from Hereditary Breast and Ovarian Cancer (HBOC) syndrome, who are at higher risk of suffering from cancer will positively impact business growth.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1922

U.S. esoteric testing market accounted for around 35% of the global industry share in 2017. Increasing prevalence of rare and complex diseases along with advancements in medical research will drive U.S. esoteric testing market over the coming years. Government initiated programs such as Obama Precision Medicine Initiative should positively impact industry growth.

Esoteric Testing Market by Test-type
o Endocrinology
o Infectious disease & immunology
o Oncology
o Toxicology
o Neurology
o Genomics

Esoteric Testing Market by Technology
o Mass spectrometry
o Flow cytometry
o ELISA
o Radioimmunoassay
o Chemiluminescence
o RT-PCR

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.